Cellular uptake of coumarin-6 as a model drug loaded in solid lipid nanoparticles

Journal of Physiology and Pharmacology

Volumn 62, Issue 1, 2011, Pages 45-53

  Rivolta, Ilaria ^a   Panariti, A ^a   Lettiero, B ^a   Sesana, S ^a   Gasco, P ^b   Gasco, M R ^b   Masserini, M ^a   Miserocchi, G ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b NANOVECTOR S R L   (Italy)

Author keywords

Coumarin 6; Differential scanning calorimetry; Effect of temperature on uptake; Nanoparticles uptake; Reactive oxigen species; Solid lipid nanoparticles

Indexed keywords

COUMARIN; COUMARIN 6; FATTY ACID; SOLID LIPID NANOPARTICLE; TRIACYLGLYCEROL; TRIPALMITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOCOMPATIBILITY; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHEMICAL INTERACTION; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG UPTAKE; EMBRYO; EXTRACELLULAR MATRIX; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; INCUBATION TEMPERATURE; INTRACELLULAR SIGNALING; LIPOPHILICITY; LUNG ALVEOLUS EPITHELIUM; MELTING POINT; MICROEMULSION; NONHUMAN; TRANSITION TEMPERATURE;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; COS CELLS; COUMARINS; DRUG CARRIERS; EPITHELIAL CELLS; FATTY ACIDS; HEK293 CELLS; HUMANS; LIPIDS; MATERIALS TESTING; NANOPARTICLES; PULMONARY ALVEOLI; TEMPERATURE; THIAZOLES; TRANSPORT VESICLES; TRIGLYCERIDES;

EID: 79954463952     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Eur J Pharmacol 2006; 533: 341-350.
2. Siekmeier R, Scheuch G. Systemic treatment by inhalation of macromolecules- principles, problems and examples. J Physiol Pharmacol 2008; 59: 53-79.
3. Muhlfeld C, Rothen-Rutishauser B, Blank F, Vanhecke D, Ochs M, Gehr P. Interaction of nanoparticles with pulmonary structures and cellular responses. Am J Lung Cell Mol Physiol 2008; 294: L817-L829.
4. Kraft KS, Grant M. Preparation of macromoleculecontaining dry powders for pulmonary delivery. Meth Mol Biol 2009; 480: 165-174.
5. Tomoda K, Ohkoshi T, Nakajima T, Makino K. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf B Biointerfaces 2008; 64: 70-76.
6. Dailey LA, Jekel N, Fink L, et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery system in the lung. Toxicol Appl Pharmacol 2006; 215: 100-108.
7. Siekmeier R, Scheuch G. Treatment of systemic diseases by inhalation of biomolecules aerosol. J Physiol Pharmacol 2009; 60: 15-26.
8. Brandenberger C, Muhlfeld C, Ali Z, et al. Quantitative evaluation of cellular uptake and trafficking of plain and polyethylene glycol-coated gold nanoparticles. Small 2010; 6: 1669-1678.
9. Lenz AG, Karg E, Lentner B, et al. A dose-controlled system for air-liquid interface cell exposure and application to zinc oxide nanoparticles. Part Fibre Toxicol 2009; 6: 32.
10. Aufderheide M, Knebel JW, Ritter D. Novel approaches for studying pulmonary toxicity in vitro. Toxicol Lett 2003; 140-141: 205-211.
11. Suarez S, O'Hara P, Kazantseva M, et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001; 18: 1315-1319.
12. Bakshi MS, Zhao L, Smith R, Possmayer F, Peterse NO. Metal nanoparticle pollutants interfere with pulmonary surfactant function in vitro. Biophys J 2008; 94: 855-868.
13. Erickson B, DiMaggio S, Mulle DG, et al. Interaction of poly(amidoamine) dendrimers with survanta lung surfactant: the importance of lipid domains. Langmuir 2008; 24: 11003-11008.
14. Zhiqing L, Zhuge X, Fuhuan C, et al. ICAM-1 and VCAM- 1 expression in rat aortic endothelial cells after single-walled carbon nanotube exposure. J Nanosci Nanotechnol 2010; 10: 8562-8574.
15. Wang X, Zang JJ, Wang H, et al. Pulmonary toxicity in mice exposed to low and medium doses of water-soluble multiwalled carbon nanotubes. J Nanosci Nanotechnol 2010; 10: 8516-8526.
16. Gasser M, Rothen-Rutishauser B, Krug HF, et al. The adsorption of biomolecules to multi-walled carbon nanotubes (MWCNTs) is influenced by both pulmonary surfactant lipids and surface chemistry. J Nanobiotechnol 2010; 8: 31.
17. Muller RH, Kader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery. A review of the state of the art. Eur J Pharm Biopharm 2000; 50: 161-177.
18. Panariti A, Rivolta I, Lettiero B, Chirico G, Gasco P, Miserocchi G. SLN as vehicle for a model drug: a biophysical study. AIP Conference Proceedings 2010; 1275: 115-117.
19. Botto L, Beretta E, Bulbarelli A, et al. Hypoxia-induced modifications in plasma membranes and lipid microdomains in A549 cells and primary human alveolar cells. J Cell Biochem 2008; 105: 503-513.
20. Steinman RM, Mellman IS, Muller WA, Cohn ZA. Endocytosis and the recycling of plasma membrane. J Cell Biol 1983; 96: 1-27.
21. Muller RH, Runge SA, Ravelli V, Thunemann AF, Mehnert W, Souto EB. Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 2008; 68: 535-544.
22. Lepock JR, Frey HE, Ritchie KP. Protein denaturation in intact hepatocytes and isolated cellular organelles during heat shock. J Cell Biol 1993; 122: 1267-1276.
23. Masserini M, Pitto M, Raimondo F, Cazzaniga E, Sesana S, Bellini T. Methyl-b-cyclodextrin treatment affects the thermotropic behaviour of membranes and detergentresistant membrane fractions of cultured A431 cells. Biol Pharm Bull 2005; 28: 2185-2188.
24. Lv Q, Yu A, Xi Y, et al. Development and evaluation of penciclovir-loaded solid lipid nanoparticles for topical delivery. Int J Pharm 2009; 372: 191-198.
25. Priano L, Esposti D, Esposti R, et al. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery system. J Nanosci Nanotechnol 2007; 7: 3596-3601.
26. Kuchler S, Radowski MR, Blaschke T, et al. Nanoparticles for skin penetration enhancement - a comparison of a dendritic core-multishell-nanotransporter and solid lipid nanoparticles. Eur J Pharm Biopharm 2009; 71: 243-250.
27. Kuchler S, Herrmann W, Panek-Minkin G, et al. SLN for topical application in skin diseases - characterization of drug-carrier and carrier-target interaction. Int J Pharm 2010; 390: 225-233.
28. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech 2007; 8: E1-E9.
29. Yang S, Zhu J, Lu Y, Liang B, Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 1999; 16: 751-757.
30. Holpuc AS, Hummel GJ, Tong M, et al. Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies. Pharm Res 2010; 27: 1224-1236.
31. Hauss DJ, Fogal SE, Ficorilli JV, Ahuss DJ, et al. Lipidbased delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 1998; 87: 164-169.
32. Cavalli R, Bargoni A, Podio V, Muntoni E, Zara GP, Gasco MR. Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 2003; 92: 1085-1094.
33. Zara GP, Cavalli R, Bargoni A, Fundarn A, Vighetto D, Gasco MR. Intravenous administration to rabbits of nonstealth and stealth doxorubicin loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and in other tissues J Drug Target 2002; 10: 327-335.
34. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238: 241-245.
35. del Pozo-Rodriguez A, Delgado D, Solinis MA, Gascon AR, Pedraz JL. Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells. Int J Pharm 2008; 360: 177-183.
36. Serpe L, Guido M, Canaparo R, et al. Intracellular accumulation and cytotoxicity of doxorubicin with different pharmaceutical formulations in human cancer cells. J Nanosci Nanotecnol 2006; 6: 3062-3069.
37. Dianzani C, Cavalli R, Zara GP, et al. Cholestryl butyrate solid lipid nanoparticles inhibit adhesion of human neutrophils to endothelial cells. Br J Pharmacol 2006; 148: 648-656.
38. Brioschi A, Zenga F, Zara GP, Gasco MR, Ducati A, Mauro A. Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors? Neurol Res 2007; 29: 324-330.
39. Cavalli R, Caputo O, Carlotti ME, Trotta M, Scarnecchia C, Gasco MR. Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 1997; 148: 47-54.
40. Cryan S. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 2005; 7: E20-E41.
41. Nassimi M, Schleh C, Lauenstein HD, et al. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur J Pharm Biopharm 2010; 75: 107-116.
42. Kovacic P, Somanathan R. Biomechanisms of nanoparticles (toxicants, antioxidants and therapeutics): electron transfer and reactive oxygen species. J Nanosci Nanotechnol 2010; 10: 7919-7930.
43. Potter TM, Neun BW, Stern ST. Assay to detect lipid peroxidation upon exposure to nanoparticles. Meth Mol Biol 2011; 697: 181-189.
44. Nielsen MB, Christensen ST, Hoffmann EK. Effects of osmotic stress on the activity of MAPKs and PDGFR-betamediated signal transduction in NIH-3T3 fibroblasts. Am J Physiol Cell Physiol 2008; 294: C1046-C1055.
45. Teskac K, Kristl J. The evidence for solid lipid nanoparticles mediated cell uptake of resveratol. Int J Pharm 2010; 390: 61-69.
46. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin and caveolae-mediated endocytosis. Biochem J 2004; 377: 159-179.
47. Pietzonka P, Rothen-Rutishauser B, Langguth P, Wunderli- Allenspach H, Walter E, Merklel HP. Transfer of lipophilic markers from PLGA and polystyrene nanoparticles to Caco- 2 monolayers mimics particle uptake. Pharm Res 2002; 19: 595-561.
48. Partlow KC, Lanza GM, Wickline SA. Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery. Biomaterials 2008; 23: 3367-3375.